Fresenius Medical Care AG & Co. KGaA FMCQF OTC · Healthcare · Germany
$47.84 +0.00% +$0.00
Summary
59 / 100 · Bulios Score
What speaks for it
- The share price is below the Bulios Fair Price.
- Earnings per share grew by 13% a year over the last 3 years.
- It bought back its own shares for 585.1M € in the last fiscal year, 5.1% of its market value.
What to watch
- Revenue grew by only 0.4% a year over the last 3 years.
- It missed profit estimates 5 times in the last 8 quarters.
- Out of every 100 EUR of revenue, only 4.2 EUR is left as net profit.
- It earns only 5.7 EUR a year on every 100 EUR of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 13.9 EUR for 1 EUR of yearly profit. Over the last five years it was 17.6 EUR on average.
Valuation in detailIs it growing?
SlowlyRevenue (EUR)
Diluted EPS (EUR)
- Analyst estimate
Revenue grew by 1.9% a year over 5 years. Over the last 3 years it grew by 0.4% a year. For the next fiscal year analysts expect revenue to fall by 0.2%. Earnings per share grew by 13% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 EUR of revenue goes
- Cost of sales 73 EUR
- Research and development 0.8 EUR
- Sales and administration 15 EUR
- Taxes and other 5.8 EUR
- Net profit 4.2 EUR
Net profit, industry median (Medical - Care Facilities) 7.2 EUR
Out of every 100 EUR of revenue, 4.2 EUR is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 6.1 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Moderate, stretched- Yield
- 3.61%
- Paid out of profit
- 50%
You receive $1.73 per share a year. The payout takes a large part of its profit or free cash flow.
Dividends in detailWhat do analysts expect?
Neutral- Buy 7
- Hold 9
- Sell 0
No analyst has published a price target.
44% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Health Care Services 75%
- Health Care Products 25%
By region
- United States 97%
- Germany 3.4%
Health Care Services brings in 75% of revenue. Health Care Products grew fastest, by 4.3% a year.
Segments in detail